Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 2/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754633 | 0.86 | AGTR2 (0.36) | AGTR2CHRM1 | |
| SCHEMBL13874224 | 0.72 | KCNH2 (0.36) | SIGMAR1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL4167648 | 0.71 | KCNH2 (0.35) | SIGMAR1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL4167653 | 0.71 | KCNH2 (0.35) | SIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL5416158 | 0.68 | CYP2D6 (0.39) | SIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL4689594 | 0.68 | CYP2D6 (0.39) | SIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL13874780 | 0.68 | CYP2D6 (0.39) | SIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL827994 | 0.66 | — | — | |
| SCHEMBL20756261 | 0.66 | L3MBTL3 (0.50) | CYP2D6CYP2C19 | |
| SCHEMBL26394048 | 0.66 | L3MBTL3 (0.50) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | AGTR2 2816/4885RAD52 880/4885SIGMAR1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.